{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:30:26Z","timestamp":1790433026990,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.tice.2024.102624","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:26:34Z","timestamp":1732033594000},"page":"102624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Targeting cancer-associated fibroblasts with pirfenidone: A novel approach for cancer therapy"],"prefix":"10.1016","volume":"91","author":[{"given":"Nima","family":"Rastegar-Pouyani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadeseh Haji","family":"Abdolvahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Farzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2024.102624_bib1","article-title":"Cancer statistics, 2024","author":"Siegel","year":"2024","journal-title":"CA: A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s40001-023-01275-4","article-title":"Repurposing approved non-oncology drugs for cancer therapy: A comprehensive review of mechanisms, efficacy, and clinical prospects","volume":"28","author":"Mohi-Ud-Din","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.tice.2024.102624_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11764-013-0272-z","article-title":"Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies","volume":"7","author":"Simard","year":"2013","journal-title":"J. Cancer Surviv."},{"issue":"3","key":"10.1016\/j.tice.2024.102624_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/targets2030015","article-title":"Systematic reversal of drug resistance in cancer","volume":"2","author":"Zhu","year":"2024","journal-title":"Targets"},{"key":"10.1016\/j.tice.2024.102624_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110525","article-title":"NF-kappaB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity","volume":"130","author":"Xu","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"3","key":"10.1016\/j.tice.2024.102624_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.14791\/btrt.2022.0018","article-title":"Managing side effects of cytotoxic chemotherapy in patients with high grade gliomas","volume":"10","author":"Ha","year":"2022","journal-title":"Brain Tumor Res. Treat."},{"issue":"6","key":"10.1016\/j.tice.2024.102624_bib7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3109\/03602538308991425","article-title":"Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man","volume":"14","author":"Powis","year":"1983","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.tice.2024.102624_bib8","article-title":"The trajectory of oral mucositis in head and neck cancer patients undergoing radiotherapy and its influencing factors","volume":"1455613241228211","author":"Liu","year":"2024","journal-title":"Ear Nose Throat J."},{"issue":"5","key":"10.1016\/j.tice.2024.102624_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3322\/caac.21689","article-title":"Radiation therapy-associated toxicity: etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tice.2024.102624_bib11","article-title":"Diversity and biology of cancer-associated fibroblasts","author":"Biffi","year":"2020","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tice.2024.102624_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121048","article-title":"Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and\/or anti-SARS-CoV-2","author":"Antar","year":"2022","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.tice.2024.102624_bib14","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.2174\/0929867327999200730173748","article-title":"Repurposing anticancer drugs for the treatment of idiopathic pulmonary fibrosis and antifibrotic drugs for the treatment of cancer: state of the art","volume":"28","author":"Paliogiannis","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.tice.2024.102624_bib15","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/jcb.27703","article-title":"Cancer-associated fibroblasts: secretions, interactions, and therapy","volume":"120","author":"Farhood","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.tice.2024.102624_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","article-title":"Cancer-associated fibroblasts in the single-cell era","volume":"3","author":"Lavie","year":"2022","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.tice.2024.102624_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J. Exp. Med"},{"issue":"2","key":"10.1016\/j.tice.2024.102624_bib18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.tice.2024.102624_bib19","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.3390\/cancers13143466","article-title":"Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy?","volume":"13","author":"Belhabib","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tice.2024.102624_bib20","first-page":"2823","article-title":"Nano-drug delivery systems targeting CAFs: a promising treatment for pancreatic cancer","author":"Wang","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"5","key":"10.1016\/j.tice.2024.102624_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13592","article-title":"Single-cell RNA sequencing to explore cancer-associated fibroblasts heterogeneity:\u201cSingle\u201d vision for \u201cheterogeneous\u201d environment","volume":"57","author":"Zhang","year":"2024","journal-title":"Cell Prolif."},{"issue":"8","key":"10.1016\/j.tice.2024.102624_bib22","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","article-title":"Phenotype molding of stromal cells in the lung tumor microenvironment","volume":"24","author":"Lambrechts","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.tice.2024.102624_bib23","article-title":"A pan-cancer single-cell transcriptional analysis of antigen-presenting cancer-associated fibroblasts in the tumor microenvironment","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.tice.2024.102624_bib24","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.tice.2024.102624_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.tice.2024.102624_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/13543780903501539","article-title":"Pirfenidone: an anti-fibrotic therapy for progressive kidney disease","volume":"19","author":"Cho","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/j.tice.2024.102624_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.tice.2024.102624_bib28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/pharmaceutics13030302","article-title":"Drug repurposing in the COVID-19 era: insights from case studies showing pharmaceutical peculiarities","volume":"13","author":"Gatti","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5-6","key":"10.1016\/j.tice.2024.102624_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000496831","article-title":"Antifibrotic agent pirfenidone suppresses proliferation of human pancreatic cancer cells by inducing G0\/G1 cell cycle arrest","volume":"103","author":"Usugi","year":"2019","journal-title":"Pharmacology"},{"key":"10.1016\/j.tice.2024.102624_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663203","article-title":"Regulatory immune cells in idiopathic pulmonary fibrosis: friends or foes?","volume":"12","author":"van Geffen","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1824631","article-title":"Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice","volume":"9","author":"Qin","year":"2020","journal-title":"Oncoimmunology"},{"issue":"75","key":"10.1016\/j.tice.2024.102624_bib32","doi-asserted-by":"crossref","first-page":"34090","DOI":"10.18632\/oncotarget.26124","article-title":"Complex formation between platelet-derived growth factor receptor \u03b2 and transforming growth factor \u03b2 receptor regulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts","volume":"9","author":"Aoto","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.tice.2024.102624_bib33","article-title":"Multifunctional ZnO@CuS nanoparticles cluster synergize chemotherapy and photothermal therapy for tumor metastasis","volume":"34","author":"Deng","year":"2021","journal-title":"Nanomedicine"},{"issue":"5","key":"10.1016\/j.tice.2024.102624_bib34","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1039\/D0BM01878C","article-title":"On-demand responsive nanoplatform mediated targeting of CAFs and down-regulating mtROS-PYK2 signaling for antitumor metastasis","volume":"9","author":"Zuo","year":"2021","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67904-8","article-title":"Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer","volume":"10","author":"Fujiwara","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib36","article-title":"CAFs homologous biomimetic liposome bearing BET inhibitor and pirfenidone synergistically promoting antitumor efficacy in pancreatic ductal adenocarcinoma","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.tice.2024.102624_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114015","article-title":"Pirfenidone inhibits stromal collagen deposition and improves intra-tumoral delivery and antitumor efficacy of Pegylated liposomal doxorubicin","volume":"157","author":"Cai","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"50","key":"10.1016\/j.tice.2024.102624_bib38","doi-asserted-by":"crossref","first-page":"82889","DOI":"10.18632\/oncotarget.12658","article-title":"Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer","volume":"7","author":"Takai","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.tice.2024.102624_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbrc.2015.04.107","article-title":"Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy","volume":"462","author":"Choi","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tice.2024.102624_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12885-016-2162-z","article-title":"The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts","volume":"16","author":"Mediavilla-Varela","year":"2016","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.tice.2024.102624_bib41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/intbio\/zyaa014","article-title":"Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta","volume":"12","author":"Aboulkheyr Es","year":"2020","journal-title":"Integr. Biol. (Camb. )"},{"issue":"20","key":"10.1016\/j.tice.2024.102624_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205118","article-title":"Pirfenidone reduces epithelial-mesenchymal transition and spheroid formation in breast carcinoma through targeting cancer-associated fibroblasts (CAFs)","volume":"13","author":"Es","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"31","key":"10.1016\/j.tice.2024.102624_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202303230","article-title":"Cancer-associated fibroblast-induced remodeling of tumor microenvironment in recurrent bladder cancer","volume":"10","author":"Liang","year":"2023","journal-title":"Adv. Sci."},{"issue":"6","key":"10.1016\/j.tice.2024.102624_bib44","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s13577-022-00766-6","article-title":"Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells","volume":"35","author":"Liu","year":"2022","journal-title":"Human Cell"},{"issue":"8_ement","key":"10.1016\/j.tice.2024.102624_bib45","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1158\/1538-7445.AM2013-4948","article-title":"Pirfenidone as a potential therapeutic treatment for CAFs and cancer cells in NSCLC","volume":"73","author":"Mediavilla-Varela","year":"2013","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.tice.2024.102624_bib46","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3390\/cancers14051231","article-title":"Cancer-associated fibroblasts: mechanisms of tumor progression and novel therapeutic targets","volume":"14","author":"Czekay","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.tice.2024.102624_bib47","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3390\/cancers7040902","article-title":"Cancer-associated fibroblasts: their characteristics and their roles in tumor growth","volume":"7","author":"Shiga","year":"2015","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.tice.2024.102624_bib48","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/cancers13061399","article-title":"The role of cancer-associated fibroblasts in tumor progression","volume":"13","author":"Joshi","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.tice.2024.102624_bib49","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","article-title":"Metastasis","volume":"186","author":"Gerstberger","year":"2023","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.tice.2024.102624_bib50","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.3390\/cancers13184720","article-title":"The role of cancer-associated fibroblasts in cancer invasion and metastasis","volume":"13","author":"Asif","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.tice.2024.102624_bib51","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.7150\/ijbs.87680","article-title":"Fibroblasts: invigorated targets in pre-metastatic niche formation","volume":"20","author":"Han","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.tice.2024.102624_bib52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mco2.55","article-title":"Molecular mechanisms of chemo-and radiotherapy resistance and the potential implications for cancer treatment","volume":"2","author":"Liu","year":"2021","journal-title":"MedComm"},{"issue":"2","key":"10.1016\/j.tice.2024.102624_bib53","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/cells9020428","article-title":"Epithelial to mesenchymal transition: a mechanism that fuels cancer radio\/chemoresistance","volume":"9","author":"Dud\u00e1s","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tice.2024.102624_bib55","series-title":"Seminars in immunology","article-title":"editors. Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies","author":"Mhaidly","year":"2020"},{"issue":"11","key":"10.1016\/j.tice.2024.102624_bib56","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1007\/s00262-023-03531-2","article-title":"PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer","volume":"72","author":"Kawasaki","year":"2023","journal-title":"Cancer Immunol., Immunother."},{"issue":"5","key":"10.1016\/j.tice.2024.102624_bib57","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","article-title":"Drug resistance in cancer: mechanisms and tackling strategies","volume":"72","author":"Haider","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.tice.2024.102624_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.tice.2024.102624_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111824","article-title":"New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities","volume":"141","author":"Ashrafizadeh","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tice.2024.102624_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155709","article-title":"TGF-beta signaling in cancer radiotherapy","volume":"148","author":"Wang","year":"2021","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.tice.2024.102624_bib61","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/07357907.2023.2237576","article-title":"The impact of Cancer-Associated Fibroblasts on drug resistance, stemness, and epithelial-mesenchymal transition in Bladder Cancer: a comparison between recurrent and non-recurrent patient-derived CAFs","volume":"41","author":"Rastegar-Pouyani","year":"2023","journal-title":"Cancer Investig."},{"issue":"9","key":"10.1016\/j.tice.2024.102624_bib62","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tice.2024.102624_bib64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","article-title":"Extracellular matrix in the tumor microenvironment and its impact on cancer therapy","volume":"6","author":"Henke","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.resinv.2017.09.007","article-title":"Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone","volume":"56","author":"Miura","year":"2018","journal-title":"Respir. Investig."},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12931-016-0398-4","article-title":"A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)","volume":"17","author":"Iwata","year":"2016","journal-title":"Respir. Res."},{"issue":"11","key":"10.1016\/j.tice.2024.102624_bib67","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1111\/1759-7714.13675","article-title":"Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study","volume":"11","author":"Yamamoto","year":"2020","journal-title":"Thorac. Cancer"},{"issue":"10","key":"10.1016\/j.tice.2024.102624_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060619","article-title":"Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial","volume":"12","author":"Chen","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.tice.2024.102624_bib69","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ijrobp.2024.07.006","article-title":"Pirfenidone in the treatment of radiation-induced lung injury: a randomized, controlled, multicenter clinical trial","volume":"120","author":"Chen","year":"2024","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"key":"10.1016\/j.tice.2024.102624_bib70","unstructured":"A Phase I\/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC [Internet]. 2017. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03177291\u3009."},{"key":"10.1016\/j.tice.2024.102624_bib71","unstructured":"Application of Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma: Phase II Clinical Study [Internet]. 2023. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06142318\u3009."},{"key":"10.1016\/j.tice.2024.102624_bib72","unstructured":"A Randomized Phase 1b\/2 Clinical Trial Evaluating Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Patients With Standard Treatment Failure of Advanced or Metastatic pMMR\/MSS Colorectal Carcinoma [Internet]. 2024. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06484153\u3009."},{"issue":"3","key":"10.1016\/j.tice.2024.102624_bib73","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/21541248.2016.1210369","article-title":"Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer","volume":"8","author":"Kitai","year":"2017","journal-title":"Small GTPases"},{"issue":"3","key":"10.1016\/j.tice.2024.102624_bib74","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.tice.2024.102624_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047024","article-title":"Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials","volume":"7","author":"Jiang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tice.2024.102624_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217287","article-title":"Pirfenidone antagonizes TGF-\u03b21-mediated gabapentin resistance via reversal of desmoplasia and the \u2018cold\u2019 microenvironment in pancreatic cancer","volume":"605","author":"Zhang","year":"2024","journal-title":"Cancer Lett."},{"issue":"93","key":"10.1016\/j.tice.2024.102624_bib77","doi-asserted-by":"crossref","first-page":"12417","DOI":"10.1039\/D1CC04846E","article-title":"Nanoscale covalent organic frameworks: from controlled synthesis to cancer therapy","volume":"57","author":"He","year":"2021","journal-title":"Chem. Commun. (Camb. )"},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib78","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.tice.2024.102624_bib79","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.5114\/aoms\/134059","article-title":"Novel green synthesis of silver nanoparticles mediated by Curcumae kwangsiensis for anti-lung cancer activities: a preclinical trial study","volume":"19","author":"Liu","year":"2023","journal-title":"Arch. Med Sci."},{"key":"10.1016\/j.tice.2024.102624_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2021.110683","article-title":"Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery","volume":"158","author":"Singh","year":"2021","journal-title":"Eur. Polym. J."},{"issue":"19","key":"10.1016\/j.tice.2024.102624_bib81","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.2174\/0929867327666201005111722","article-title":"Nanocarrier-based drug delivery system for cancer therapeutics: a review of the last decade","volume":"28","author":"Sohail","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.tice.2024.102624_bib82","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/cgt.2017.9","article-title":"The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: A systematic review of clinical trials","volume":"24","author":"Ansari","year":"2017","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.tice.2024.102624_bib83","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2019.01.045","article-title":"Aptamer-functionalized liposomes for targeted cancer therapy","volume":"448","author":"Moosavian","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tice.2024.102624_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2021.110683","article-title":"Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery","volume":"158","author":"Singh","year":"2021","journal-title":"Eur. Polym. J."},{"issue":"4","key":"10.1016\/j.tice.2024.102624_bib85","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/jcp.26029","article-title":"Nanoparticles as new tools for inhibition of cancer angiogenesis","volume":"233","author":"Hashemi Goradel","year":"2018","journal-title":"J. Cell Physiol."},{"issue":"5","key":"10.1016\/j.tice.2024.102624_bib86","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/anie.201915826","article-title":"Smart design of nanomaterials for mitochondria-targeted nanotherapeutics","volume":"60","author":"Liew","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.tice.2024.102624_bib87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2014.02.010","article-title":"The potential of heparanase as a therapeutic target in cancer","volume":"89","author":"Pisano","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tice.2024.102624_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.tice.2024.102624_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-021-02179-4","article-title":"Strategies for liposome drug delivery systems to improve tumor treatment efficacy","volume":"23","author":"Wang","year":"2022","journal-title":"Aaps Pharmscitech"},{"issue":"2","key":"10.1016\/j.tice.2024.102624_bib90","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/acsmaterialslett.3c01265","article-title":"Fe-mediated self-assembled nanodrug for tumor microenvironment activated synergistic ferroptosis-based-chemodynamic\/chemo therapy and magnetic resonance imaging","volume":"6","author":"Xu","year":"2024","journal-title":"ACS Mater. Lett."},{"issue":"10","key":"10.1016\/j.tice.2024.102624_bib91","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1111\/cas.15929","article-title":"Fibroblast inhibition by tocilizumab enabled gemcitabine\/nab-paclitaxel rechallenge for pancreatic cancer","volume":"114","author":"Mitsunaga","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tice.2024.102624_bib92","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coi.2020.03.004","article-title":"Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy","volume":"64","author":"Barrett","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.tice.2024.102624_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121575","article-title":"Activated fibroblasts in cardiac and cancer fibrosis: An overview of analogies and new potential therapeutic options","volume":"321","author":"Nicolini","year":"2023","journal-title":"Life Sci."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816624003252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816624003252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T04:09:54Z","timestamp":1733544594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816624003252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":93,"alternative-id":["S0040816624003252"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2024.102624","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cancer-associated fibroblasts with pirfenidone: A novel approach for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2024.102624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102624"}}